Alunbrig

Alunbrig (Brigatinib) is an oral medication used to treat certain types of cancer. This advanced therapy targets specific proteins to help manage the progression of the disease.

Alunbrig is primarily used in the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. It is designed for patients who have specific genetic mutations, such as those with ALK-positive NSCLC. The medication works by targeting and inhibiting certain proteins that contribute to cancer cell growth. Patients often wonder, 'What is Alunbrig used for?' and the answer lies in its role in managing advanced forms of lung cancer.

Common effects of Alunbrig may include fatigue, nausea, and cough. Some patients may experience changes in liver function or lung issues. It is important to monitor these effects and consult a healthcare provider if they become severe or persistent.

Alunbrig should be handled with care and stored as directed. It is crucial to follow the prescribed dosage and administration instructions. Patients should inform their healthcare provider about any other medications they are taking to avoid potential interactions.

Alunbrig may interact with certain medications, including those that affect liver enzymes. It is important to discuss all current medications with a healthcare provider to ensure safe use. Alcohol and other substances that affect liver function should be avoided.